Matthias Heck is Senior Advisor at the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He focuses on partnership building and provides strategic guidance on legislative and policy matters. A German-qualified lawyer with some 20 years of experience in life sciences, Matthias has extensive expertise in market access and policy engagement at national and European levels. For the past decade he's worked in the pharmaceutical industry in the rare disease space, building multi-stakeholder partnerships, negotiating access for individual rare disease treatments, and working on rare disease policy and legislation.
Over the past decade, newborn screening programs throughout Europe have seen significant advancements, both in the number of countries adopting them and the variety of disorders they screen for. Despite this progress, considerable disparities remain between countries, with the number of screened conditions varying widely. This session will explore the reasons behind these inequalities and discuss the advantages of achieving more equitable access to newborn screening across Europe for both patients and society.